Objective: Online platforms have created a variety of opportunities for breast patients to discuss their hormonal therapy, a long-term adjuvant treatment to reduce the chance of breast cancer occurrence and mortality. The goal of this investigation is to ascertain the extent to which the messages breast cancer patients communicated through an online portal can indicate their potential for discontinuing hormonal therapy. Materials and Methods: We studied the de-identified electronic medical records of 1106 breast cancer patients who were prescribed hormonal therapy at Vanderbilt University Medical Center over a 12-year period. We designed a data-driven approach to investigate patients' patterns of messaging with healthcare providers, the topics they communicated, and the extent to which these messaging behaviors associate with the likelihood that a patient will discontinue a prescribed 5-year regimen of therapy. Results: The results indicates that messaging rate over time [hazard ratio (HR) ¼ 1.373, P ¼ 0.002], mentions of side effects (HR ¼ 1.214, P ¼ 0.006), and surgery-related topics (HR ¼ 1.170, P ¼ 0.034) were associated with increased risk of early medication discontinuation. In contrast, seeking professional suggestions (HR ¼ 0.766, P ¼ 0.002), expressing gratitude to healthcare providers (HR ¼ 0.872, P ¼ 0.044), and mentions of drugs used to treat side effects (HR ¼ 0.807, P ¼ 0.013) were associated with decreased risk of medication discontinuation. Discussion and Conclusion: This investigation suggests that patient-generated content can inform the study of health-related behaviors. Given that approximately 50% of breast cancer patients do not complete a course of hormonal therapy as described, the identification of factors associated with medication discontinuation can facilitate real-time interventions to prevent early discontinuation.
BACKGROUND AND SIGNIFICANCE
User generated content (UGC) in online environments is increasingly supplementing traditional electronic medical records (EMRs) in biomedical research. 1 Prior studies have focused on public health surveillance, 2 patient privacy, 3, 4 shifts in suicidal ideation, 5 medication discontinuation, 6, 7 content mining, 8, 9 sentiments and emotions, 6, 10, 11 and the impact of social support and influence among patients. [12] [13] [14] There is evidence that combining data streams can enable new types of investigations, such as early detection of adverse drug events. 15 While social media dominates the field of UGC, another type of UGC are patient-generated messages (PGMs) communicated through the messaging service in online patient portals. Most research on PGM to date has focused on metadata such as messaging volume. For instance, it has been shown that frequent usage of a portal service is associated with better diabetic control [16] [17] [18] as well as reductions in outpatient and inpatient healthcare utilization. [19] [20] [21] More recently, there have been investigations into the content of PGMs. [22] [23] [24] However, these studies are limited in several important ways. First, they tend to rely on humans to manually review and annotate message instances, 22 a process that is both time consuming and lacks scalability. Alternatively, some investigations have applied supervised learning to classify the topics inherent in the messages, which addresses the issue of scalability, but fails to detect topics that are not defined a priori or are not found in training data. 23, 24 To the best of our knowledge, there are no studies that focus on linking PGM content to health outcomes and behaviors. Since PGMs communicated through a patient portal may contain factors that are not captured in the structured portions of EMRs, they provide a novel opportunity to help learn the state of the patient.
Here, we describe a study based on the hypothesis that patients' messaging behaviors, in terms of messaging rate and topics discovered through unsupervised methods, will associate with medication discontinuation. To investigate this hypothesis, we focused on a cohort of breast cancer patients prescribed hormonal therapy at Vanderbilt University Medical Center (VUMC). We focus on this subpopulation because, while hormonal therapy has been proven as an efficient long-term adjuvant treatment for patients with hormone receptor-positive breast cancer, rates of early discontinuation are as high as 50%. 25, 26 While some factors that may trigger a patient to stop using a hormonal therapy medication, such as high cost or intolerable side effects, have been elucidated, there remains a major unmet need to recognize patients at risk of early discontinuation. 11, [27] [28] [29] Traditional investigations into hormonal therapy discontinuation tend to rely on information gathered through surveys with patients or data derived from EMRs. 28, [30] [31] [32] However, as noted in a recent study, 6 these types of data sources are limited by the fact that they rely on non-scalable methods (eg, surveys) or lack information other than healthcare provider observations. In contrast, there is increasing evidence that UGC from online environments can be utilized to learn factors related to hormonal therapy discontinuation. For instance, we previously demonstrated that data from an online breast cancer forum suggested that patients who mentioned side effects, such as depression, were more likely to discontinue hormonal therapy. 6, 7 Additionally, many potential barriers to breast cancer treatments (eg, cost and trust) can be detected in UGC from the online environment. 33 Yet, despite the opportunities these new domains support, there are no studies that examine the factors inferred from PGMs or their association with hormonal therapy discontinuation. This is notable because the PGMs in patient portals (which could be contributed by patients or their delegates, such as a spouse) can be linked to a patient's EMRs, thus making it feasible to directly investigate such associations.
METHODS

Data preparation
Study population This study is based on de-identified data from the patient portal and EMRs of VUMC and was approved as non-human subject research by the Vanderbilt University institutional review board. 34 All patient identities were replaced with persistent pseudonyms by a third-party honest broker, and all dates within a record were consistently offset by a number of days uniformly sampled from a (-365,-1) range. We focus on patients who were diagnosed with American Joint Committee on Cancer (AJCC) summary stage I to III invasive breast cancer, and were prescribed any of the following hormonal therapy medications: anastrozole, exemestane, letrozole (aromatase inhibitors; AIs), or raloxifene, tamoxifen (selective estrogen receptor modulators; SERMs). 35 We constrain the study to breast cancer patients who commenced their treatment after the date of the first PGM sent by breast cancer patients, which took place in late 2005. Deceased patients before March 2017, the end of data collection window, were excluded due to their unresolved medication discontinuation status.
Determining the medication discontinuation events Most guidelines specify AIs and/or SERMs for at least 5 years as an adjuvant treatment protocol; 36 we thus focus on discontinuation events within the first 5 years of hormonal therapy. Figure 1 illustrates the critical time points that define a medication discontinuation event. Specifically, we estimate the event at 6 months after the maximum medication entry date (denoted as T maxþ0:5 ) within a 5-year period, as breast cancer patients prescribed hormonal therapy are expected to have a clinic encounter every 6 months in the first 5 years after diagnosis. 35 For patients with their T maxþ0:5 beyond the data collection window, because we do not observe a full 5 years length of records, they are right-censored in the survival analysis (see below). Using a 12-year data collection window, we obtained 245 (22.2%) right-censored patients, 478 (53.2%) patients finishing a 5-year protocol, and 383 (34.6%) patients who failed to complete the treatment regimen. This latter observation is consistent with a systematic review that indicated early discontinuation rates of hormonal therapy range from 31% to 73%. 37 
Messaging patterns
Messaging volume
To investigate the relationship between messaging volume and medication discontinuation, we focus on the patients who either 1) completed 5 years of treatment or 2) experienced a medication discontinuation event (excluding the right-censored patients). We order the patients according to their messaging volume and apply a moving average to estimate the probability that a patient discontinues his or her medication in each window. Each window includes 12.5% of the selected patients for the risk estimation. We also apply the same moving average strategy to obtain the corresponding average log transformed messaging volumes.
Messaging rate
To obtain an overall trend of messaging rates, we set the first hormonal therapy entry date as the starting point (also known as the start of hormonal therapy treatment) and partition the timeline of messaging dates into a series of 6-month periods. In doing so, time period 0 corresponds to the first 6-month hormonal therapy treatment, while periods with negative (non-negative) index values correspond to the time before (after) hormonal therapy treatment. We calculate the messaging rate for each patient by counting the number of messages sent in each period.
Message topic inference
We infer the topics through applying a hierarchical clustering strategy directly on the words in the messages. By employing a word embedding technique, in the form of word2vec, we map words into a vector space of much lower dimensionality and calculate their semantic similarity in terms of cosine distance. 38 While topic modeling has been applied to personally contributed information, 39 our solution may generate more interpretable topics by directly combining words with similar semantics. We use a skip-gram model with negative sampling as implemented in the gensim python package (version 0.13.1) to fit a word2vec model over all of the messages. We retain the words that appear at least 5 times, choose a sliding window of 5 words in length, and set the word vector length to 200. The fitted word2vec model contained over 13 000 distinct words, many of which were unlikely to assist in understanding messaging content. As a result, we chose the 2000 most frequent, and enlarged the selected word collection by incorporating words that exhibited a cosine distance greater than 0.6 with any of the selected words. This was expected to include more words due to misspelling and semantic similarity. This process recovered an additional 2010 words. We further removed several types of words that we suspected would contribute little towards constructing meaningful topics: 1) stop words (eg, the or of); 2) years; and 3) words with a cosine distance greater than 0.6 from the words noted above. This process yielded 3664 words.
We applied an agglomerative hierarchical clustering with complete linkage implemented in the sklearn python package (version 0.18.1) to extract topics. As such, we adopted a simple metric to help decide the number of clusters: the standard deviation of cluster size. When there are more than two clusters, the standard deviation of the cluster size decreases towards zero as the number of clusters grows towards the vocabulary size with a proper step (eg, 25 in our case). This is because a small step can induce in an unsmoothed curve that is difficult to interpret for the ideal number of clusters. Based on this observation, we follow the elbow principle to locate the angle where the marginal gain in cluster size begins to diminish. This indicated that the optimal number of clusters was 200. We refer the reader to Supplementary Appendices S1 and S2 for details on the topic extraction and analysis.
Survival analysis
Model
We apply a Cox proportional hazards regression model to evaluate for associations between messaging behaviors and medication discontinuation. There are 2 primary benefits in applying a Cox model instead of a model akin to logistic regression in this study. First, Cox is a semi-parametric model that does not assume any particular survival distribution. Second, the model incorporates right-censored patients. The hazard ratio (HR) at a significance level of 0.05 will be reported.
Control variables
We incorporated 4 additional variables into the model: age at diagnosis, race, cancer stage, and hormonal therapy medication. We imputed missing values for age (1.1%) with the average age and scale the variable into the (0, 1) range. We partitioned race into White and non-White (represented as 1/0). We further categorized cancer stage into advanced/early (represented as 1/0) cancer stage. The variable of AI medication (denoted as taking AI) is represented as a proportion of the number of periods on AIs divided by the number of periods on either AIs or SERMs.
Message related predictors
We constructed 2 types of predictors related to messages. First, we built topic predictors as follows: 1) for each patient, we aggregated all the messages sent after the breast cancer diagnosis date and before either: i) when the medication discontinuation event occurred or ii) the patient was right censored. As such, we modeled each patient as a collection of messages; 2) we replaced the words in each patient message collection with the corresponding topic numbers (if present); 3) we calculated the Term Frequency-Inverse Document Frequency values for each topic in each patient message collection, which we use as topic predictor values. Second, we included messaging rate (in terms of the average number of messages sent per 6-month period) as an additional variable. AS the messaging rate distribution is right-skewed (see Supplementary Appendix S3 for a histogram of messaging rate), we applied a log transform and scaled the data into a (0, 1) range before applying the Cox model. T 0 refers to the first hormonal medication entry date, and Tmax is the maximum medication entry date. Tmaxþ0:5 re represents the 6 months after the Tmax and T5 is the end of the 5-year treatment protocol. A discontinuation event is experienced at Tmaxþ0:5 when Tmaxþ0:5 < T5 and Tmaxþ0:5 is smaller than the end of data collection window. Figure 2 depicts a log-log plot of the messaging frequency distribution. 10% of the patients sent only 1 message during the data collection window. In contrast, 0.2% of the patients sent more than 500 messages. Figure 3 illustrates the probability of discontinuing medication against the log transformed messaging volume. The figure shows that patients are less likely to discontinue medication as the number of messages they send increases. However, this trend falters when the messaging volume grows to around 3 messages on average. At this point, patients begin to exhibit an increasing risk of discontinuing their treatment regimen until the messaging volume reaches another inflection point at around 20 messages. After this point, the probability of discontinuing medication rapidly decreases. Figure 4 depicts the LOWESS smooth curve, along with its 95% confidence interval, for messaging rates along the treatment timeline. There are 3 clinically important dated events highlighted in the figure, as indicated with vertical dotted lines: left) the diagnosis of breast cancer (index ¼ -1.6, 90% percentile), middle) the start of hormonal therapy (beginning of the period with index ¼ 0), and right) completion of a 5-year treatment protocol (beginning of the period with index ¼ 10). The figure shows that breast cancer patients send messages at an increasing rate before the disease is diagnosed, suggesting increased coordination of care in the period of workup prompted by an abnormal mammogram or palpable breast lump. The messaging rate reaches its maximum just before the start of the hormonal therapy, then drops quickly in the initial 2.5 years of treatment, and holds steady until the end of the 5-year regimen. These rate changes show that breast cancer patients tend to have less communications with healthcare providers as their hormonal therapy progresses.
RESULTS
Messaging patterns
Messaging volume
Messaging rate
Survival analysis
Model fitting
We fit a Cox model with a concordance of 0.753 based on the lifelines python package (version 0.9.4). With respect to the 4 control variables, it was found that age at diagnosis is significantly associated with an increased risk of discontinuation (HR ¼ 1:173, P ¼ 0:026), while taking AI is significantly associated with a decreased risk of discontinuation (HR ¼ 0:715, P < 0:001).
Messaging rate
After controlling for the 4 variables, the average messaging rate was positively associated with discontinuation (HR ¼ 1:373, P < 0:002). In addition, many topics were found to be statistically significant. This suggests that topics contributed additional information above and beyond the messaging rate for explaining medication discontinuation. We summarized these topics, based on their increased or decreased risk, as follows. Table 1 summarizes the inferred topics that were associated with an increased risk (HR > 1) of medication discontinuation. In Table 1 , it can be seen that patients who mention tests for assessing heart damage (#126, HR ¼ 1:216) or describe common side effects caused by hormonal therapy (#13, HR ¼ 1:214; #53, HR ¼ 1:164) have an increased risk of discontinuing medications. As one patient communicated when taking tamoxifen,
Topics with increased risk
• "I am having really bad mood . . . and depression is becoming a problem. My appt is not until middle of **DATE and I don't think I can wait that long. I think its the tamoxifen that I'm taking."
Patients who mentioned breast-or ovary-related surgery (#44, HR ¼ 1:170) are more likely to discontinue medications. As one patient once wrote:
• "I just had a full hysterectomy last week and I had a bilateral mast(ectomy) at the end of **DATE. So. . .I won't feel comfortable starting any drugs, ie, Tamoxifen unless we check my blood."
Patients who discontinue medications might mention their blood test results (#0, HR ¼ 1:194). As another patient noted:
• "Ok, been off the tamoxifen for a month. I feel much better! . . .
Are there better options? Not really wanting to go back. . .. So, looking at my lab results, there appears to be a significant change in the hemoglobin, PCV, platelet and red blood cell counts. . .
Does tamoxifen cause that?"
Patients who discontinue medications also mention verbs (#189, HR ¼ 1:159) or adjectives (#79, HR ¼ 1:130) that might be related to health conditions or tests. As one patient voiced:
"Is it normal to feel a little dizzy and nauteous [sic]? It has been almost a week since my surgery."
Another topic that was associated with an increased risk of medication discontinuation corresponds to the mentions of a website (#56, HR ¼ 1:171), through which patients may conduct research or gather information. As one patient said:
• "I read online that if you are allergic to iron oxide you shouldn't take it. I think I am allergic to carbide. Would that be a problem?" • "Do I need to modify any of medications (excluding RA medications) prior or post surgery? -Tamoxifen -Zoladex Thank you for your expertise." • "Thank you so very much for our good appointment today. I really did need to see you, and I am grateful for the expertise, knowledge, and history you bring to my case and overall health issues."
Topics with decreased risk
These patients may also take drugs to cope with side effects or symptoms (#38, While there are 2 statistically significant topics (#109, #127) for which it is difficult to explain their association with medication discontinuation, most of our findings are in accordance with the literature, as discussed in the following section.
DISCUSSION
The findings of this study have several notable implications. First, the topics communicated by breast cancer patients appear to be effective indicators of medication discontinuation. In particular, we 
The topics are sorted according to HR. A larger HR suggests a greater risk of medication discontinuation. For each topic in the table, we rank the words based on their average similarity with other words in the same topic. If the size of the topic is greater than 20, we display the top 20 words; otherwise, we show all of the words in the topic. discover several topics that positively associate with medication discontinuation events and are supported by evidence in the literature. For example, gastrointestinal reactions such as nausea and vomiting (topic #13) have been shown to be risk factors of hormone therapy discontinuation. 32 Additionally, an echocardiogram (echo) or electrocardiogram (EKG) (topic #122) that was mentioned more by patients with medication discontinuation may be due to the fact that cardiac complications are also recognized as a severe side effects of AI. 40 We further observe that patients who request professional suggestions (topic #136) or express gratitude to healthcare providers (topic #105) are less likely to discontinue hormonal therapy. This finding aligns with evidence that indicates respect for the advice of their caring physicians and family members can drive breast cancer patients to adhere to prescribed treatments. 41 Furthermore, there are studies that have shown that a good relationship with one's physician and self-efficacy in taking medication are associated with better hormonal therapy adherence. 42 Meanwhile, it has been shown that managing side effects can prevent discontinuation. 43 This may explain why mentions of drugs for treating side effects were associated with decreased risk of medication discontinuation. In addition, we find that the average messaging rate correlates with an increased risk of medication discontinuation. While our messaging volume analysis shows that the probability of discontinuing medication rapidly decreases after 20 messages, as a large proportion of patients characterized by this decreasing trend completed the 5-year treatment protocol, and considering our 12-year data collection window, we suspect that these patients accumulated a high messaging volume by using the service over years of activity. This still suggests that messaging rates may be a useful indicator for predicting medication discontinuation.
Finally, it should be recognized that our data-driven approach requires minimal human efforts to analyze patient portal messages. For example, we can identify common usages of the messaging service in patient portals, which are in alignment with the findings of previous studies that rely on manually explored message content. 22 While it is appealing to apply a pre-trained word2vec model (eg, fit a model using a public dataset, such as the Google news corpus) for topic extraction, our experience with data from an online breast cancer forum suggest that training a specific word2vec model from a particular context is more effective. 6, 7 Part of the reason is that many words applied in the clinical setting are unlikely to exist in the pre-trained corpus. By invoking unsupervised methods, it may be possible to design and deploy an automated alert system to monitor patients' messages. Such a system could lower the burden of healthcare providers, as well as assist in providing interventions that assist patients in completion of long-term treatment regimens. Despite the merits of this investigation, there are several limitations that we believe can serve as the basis of future work. First, the population was derived from a single institution, which may limit the generalizability of our findings. Second, we did not distinguish between medication discontinuations that were consultative (ie, a decision made at the recommendation of the prescribing clinician, with or without shared decision making) or autonomous (ie, a patient's independent decision). This is notable because the factors influencing these scenarios may differ. As such, we believe that a natural next step to this line of research is to determine the context around a discontinuation event (if such information is available) and incorporate the scenario as a factor in the model. Third, our medication discontinuation events were determined based on medication history recorded in the EMR system, which would probably result in some degree of immortal time bias. 44 Future work could consider incorporating prescription data and patient self-report to mitigate this time lag. Fourth, because of the heavy tailed distribution of message volume, our investigation may be biased towards users who more frequently use the messaging service in patient portals.
Other future work could investigate the effectiveness of other clustering algorithms (eg, spectral clustering 45 ), as well as topic modeling 46 for topic extraction. While spectral clustering is more suitable for data that consist of connected components that are well separated (which is likely for natural language terms), topic modeling allows for a term to belong to multiple topics. We also believe it would be a fruitful endeavor to supplement the unsupervised methods with domain knowledge, so that topic extraction and selection could be guided before fitting a statistical model. We suspect this approach may be feasible, as it has shown to be beneficial in automated phenotype discovery. 47, 48 Furthermore, the message features (eg, messaging rates and topics) can be constructed as time-dependent covariates in survival analysis in order to capture their timevarying patterns and effects. Finally, we believe a predictive model can be built upon a combination of structured EMR data and PGMs. However, to make it practical for clinical decision support, further research efforts should evaluate 1) the effectiveness of combining these resources, 2) the extent to which care providers would accept such a model, and 3) what they could do with the information to impact change.
CONCLUSIONS
This investigation demonstrated the potential merits of patientcontributed information for learning medication discontinuation. Specifically, this study focused on the online portal messaging patterns and inferred topics from the messages communicated by breast cancer patients to care providers. We showed that there are associations between these factors and hormonal therapy medication discontinuation. The findings of this investigation suggest that PGMs can assist in predicting a breast cancer patients' likelihood of medication discontinuation and could serve as the basis of automated decision support tools to recognize patients at risk for discontinuation of a prescribed regimen.
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